S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in

Health Catalyst Stock Forecast, Price & News

-0.27 (-0.57 %)
(As of 03/4/2021 12:00 AM ET)
Today's Range
Now: $46.97
50-Day Range
MA: $50.12
52-Week Range
Now: $46.97
Volume713,504 shs
Average Volume486,127 shs
Market Capitalization$2.07 billion
P/E RatioN/A
Dividend YieldN/A
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.
Health Catalyst logo


Recap: Health Catalyst Q4 Earnings
February 25, 2021 |  benzinga.com
Health Catalyst (HCAT) Catches Eye: Stock Jumps 5.1%
December 14, 2020 |  finance.yahoo.com
Is HCAT A Good Stock To Buy Now?
December 13, 2020 |  finance.yahoo.com
Health Catalyst Inc (HCAT) Q3 2020 Earnings Call Transcript
November 11, 2020 |  finance.yahoo.com
Health Catalyst EPS beats by $0.06, beats on revenue
November 10, 2020 |  seekingalpha.com
Health Catalyst Reports Third Quarter 2020 Results
November 10, 2020 |  finance.yahoo.com
Health Catalyst: Q3 Earnings Insights
November 10, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Computer programming, data processing, & other computer related
Current SymbolNASDAQ:HCAT
Year FoundedN/A



Sales & Book Value

Annual Sales$154.94 million
Book Value$5.49 per share


Net Income$-60,100,000.00


Market Cap$2.07 billion
Next Earnings Date5/11/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.59 out of 5 stars

Medical Sector

365th out of 1,969 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

12th out of 74 stocks

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.27 (-0.57 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HCAT News and Ratings via Email

Sign-up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Health Catalyst (NASDAQ:HCAT) Frequently Asked Questions

Is Health Catalyst a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Health Catalyst stock.
View analyst ratings for Health Catalyst
or view top-rated stocks.

What stocks does MarketBeat like better than Health Catalyst?

Wall Street analysts have given Health Catalyst a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Health Catalyst wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Health Catalyst's next earnings date?

Health Catalyst is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Health Catalyst

How were Health Catalyst's earnings last quarter?

Health Catalyst, Inc. (NASDAQ:HCAT) posted its quarterly earnings results on Thursday, February, 25th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.23. The company had revenue of $53.28 million for the quarter, compared to analyst estimates of $52.21 million. Health Catalyst had a negative net margin of 48.17% and a negative trailing twelve-month return on equity of 25.57%.
View Health Catalyst's earnings history

How has Health Catalyst's stock price been impacted by COVID-19?

Health Catalyst's stock was trading at $27.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HCAT stock has increased by 70.3% and is now trading at $46.97.
View which stocks have been most impacted by COVID-19

What guidance has Health Catalyst issued on next quarter's earnings?

Health Catalyst issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $225.1-228.1 million, compared to the consensus revenue estimate of $225.88 million.

What price target have analysts set for HCAT?

11 brokerages have issued 12-month price objectives for Health Catalyst's shares. Their forecasts range from $36.00 to $56.00. On average, they anticipate Health Catalyst's share price to reach $45.14 in the next twelve months. This suggests that the stock has a possible downside of 3.9%.
View analysts' price targets for Health Catalyst
or view top-rated stocks among Wall Street analysts.

Who are Health Catalyst's key executives?

Health Catalyst's management team includes the following people:
  • Mr. Daniel D. Burton, CEO & Director (Age 46, Pay $497.11k)
  • Mr. Paul Horstmeier, Chief Operating Officer (Age 60, Pay $433.53k)
  • Mr. J. Patrick Nelli Jr., Pres
  • Mr. Steven C. Barlow, Co-Founder & Sr. VP
  • Mr. Thomas D. Burton, Co-Founder & Chief Learning Officer
  • Mr. Bryan Truman Hunt, Chief Financial Officer (Age 34)
  • Mr. Jason Alger, Chief Accounting Officer (Age 37)
  • Mr. Bryan Hinton, Chief Technology Officer
  • Mr. Adam Brown, Sr. VP of Investor Relations and Financial Planning & Analysis
  • Mr. Daniel H. Orenstein, Gen. Counsel & Sec. (Age 51)

What is Dan Burton's approval rating as Health Catalyst's CEO?

393 employees have rated Health Catalyst CEO Dan Burton on Glassdoor.com. Dan Burton has an approval rating of 99% among Health Catalyst's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Health Catalyst's key competitors?

What other stocks do shareholders of Health Catalyst own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA), salesforce.com (CRM), Alteryx (AYX), The Walt Disney (DIS), DocuSign (DOCU), Square (SQ), Slack Technologies (WORK), ServiceNow (NOW), Marvell Technology Group (MRVL) and PayPal (PYPL).

When did Health Catalyst IPO?

(HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

What is Health Catalyst's stock symbol?

Health Catalyst trades on the NASDAQ under the ticker symbol "HCAT."

Who are Health Catalyst's major shareholders?

Health Catalyst's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.96%), Clearbridge Investments LLC (4.56%), Alliancebernstein L.P. (4.07%), Janus Henderson Group PLC (3.38%), Victory Capital Management Inc. (2.70%) and Riverbridge Partners LLC (2.60%). Company insiders that own Health Catalyst stock include Anita Pramoda, D Fraser Bullock, Dale Sanders, Daniel D Burton, Daniel H Orenstein, James Patrick Jr Nelli, Linda Llewelyn, Paul Horstmeier and Timothy G Ferris.
View institutional ownership trends for Health Catalyst

Which major investors are selling Health Catalyst stock?

HCAT stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Price T Rowe Associates Inc. MD, FIL Ltd, Monarch Partners Asset Management LLC, Victory Capital Management Inc., Sepio Capital LP, Morse Asset Management Inc, and Credit Suisse AG. Company insiders that have sold Health Catalyst company stock in the last year include Anita Pramoda, D Fraser Bullock, Dale Sanders, Daniel D Burton, Daniel H Orenstein, James Patrick Jr Nelli, Linda Llewelyn, Paul Horstmeier, and Timothy G Ferris.
View insider buying and selling activity for Health Catalyst
or view top insider-selling stocks.

Which major investors are buying Health Catalyst stock?

HCAT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Clearbridge Investments LLC, Janus Henderson Group PLC, Laurion Capital Management LP, Ashford Capital Management Inc., Riverbridge Partners LLC, Alliancebernstein L.P., and Bellecapital International Ltd..
View insider buying and selling activity for Health Catalyst
or or view top insider-buying stocks.

How do I buy shares of Health Catalyst?

Shares of HCAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Health Catalyst's stock price today?

One share of HCAT stock can currently be purchased for approximately $46.97.

How much money does Health Catalyst make?

Health Catalyst has a market capitalization of $2.07 billion and generates $154.94 million in revenue each year. The company earns $-60,100,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.

How many employees does Health Catalyst have?

Health Catalyst employs 1,000 workers across the globe.

What is Health Catalyst's official website?

The official website for Health Catalyst is www.healthcatalyst.com.

Where are Health Catalyst's headquarters?

Health Catalyst is headquartered at 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121.

How can I contact Health Catalyst?

Health Catalyst's mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company can be reached via phone at 801-708-6800 or via email at [email protected]

This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.